Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1126 AL 1140

The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients

Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P.

Funct Neurol. 2013 Jan-Mar;28(1):13-7.

A comparison of Irish set dancing and exercises for people with Parkinson's disease: a phase II feasibility study

Volpe D, Signorini M, Marchetto A, Lynch T, Morris ME.

BMC Geriatr. 2013 Jun 4;13:54. doi: 10.1186/1471-2318-13-54.

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data

Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J.

Pharmacol Res. 2013 Aug;74:78-86. doi: 10.1016/j.phrs.2013.05.005. Epub 2013 Jun 2.

[Network analyses in neuroimaging studies]

Hirano S, Yamada M.

Brain Nerve. 2013 Jun;65(6):659-67.

[Visual cues as a therapeutic tool in Parkinson's disease. A systematic review]

Muñoz-Hellín E, Cano-de-la-Cuerda R, Miangolarra-Page JC.

Rev Esp Geriatr Gerontol. 2013 Jul-Aug;48(4):190-7. doi: 10.1016/j.regg.2013.03.002. Epub 2013 Jun 2.

Functional (psychogenic) symptoms in Parkinson's disease

Pareés I, Saifee TA, Kojovic M, Kassavetis P, Rubio-Agusti I, Sadnicka A, Bhatia KP, Edwards MJ.

Mov Disord. 2013 Oct;28(12):1622-7. doi: 10.1002/mds.25544. Epub 2013 Jun 4.

Cerebral venous infarction: a potentially avoidable complication of deep brain stimulation surgery

Morishita T, Okun MS, Burdick A, Jacobson CE 4th, Foote KD.

Neuromodulation. 2013 Sep-Oct;16(5):407-13; discussion 413. doi: 10.1111/ner.12052. Epub 2013 Jun 5.

Nonmotor symptoms in Parkinson's disease

Hussl A, Seppi K, Poewe W.

Expert Rev Neurother. 2013 Jun;13(6):581-3. doi: 10.1586/ern.13.53.

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

Naoi M, Maruyama W, Inaba-Hasegawa K.

Expert Rev Neurother. 2013 Jun;13(6):671-84. doi: 10.1586/ern.13.60.

Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease

MacArthur L, Ressom H, Shah S, Federoff HJ.

Expert Rev Neurother. 2013 Jun;13(6):685-93. doi: 10.1586/ern.13.59.

Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease

Douglas MR.

Expert Rev Neurother. 2013 Jun;13(6):695-705. doi: 10.1586/ern.13.58.

Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease

Müller T.

Expert Rev Neurother. 2013 Jun;13(6):707-18. doi: 10.1586/ern.13.50.

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease

Wright BA, Waters CH.

Expert Rev Neurother. 2013 Jun;13(6):719-29. doi: 10.1586/ern.13.47.

[Approaches to treatment optimization of depression in patients with Parkinson's disease]

Strashunskaya EY, Strashunskaya EL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(4):75-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias